Search by Drug Name or NDC
NDC 00071-0525-24 Celontin 300 mg/1 Details
Celontin 300 mg/1
Celontin is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Parke-Davis Div of Pfizer Inc. The primary component is METHSUXIMIDE.
MedlinePlus Drug Summary
Methsuximide is used to control absence seizures (petit mal; a type of seizure in which there is a very short loss of awareness during which the person may stare straight ahead or blink his eyes and does not respond to others) that cannot be treated with other medications. Methsuximide is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.
Related Packages: 00071-0525-24Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Methsuximide
Product Information
NDC | 00071-0525 |
---|---|
Product ID | 0071-0525_7125a267-65f7-40b7-88cb-fbfc4a750ef7 |
Associated GPIs | 72400020000110 |
GCN Sequence Number | 004553 |
GCN Sequence Number Description | methsuximide CAPSULE 300 MG ORAL |
HIC3 | H4B |
HIC3 Description | ANTICONVULSANTS |
GCN | 17411 |
HICL Sequence Number | 001890 |
HICL Sequence Number Description | METHSUXIMIDE |
Brand/Generic | Brand |
Proprietary Name | Celontin |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | methsuximide |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | CAPSULE |
Route | ORAL |
Active Ingredient Strength | 300 |
Active Ingredient Units | mg/1 |
Substance Name | METHSUXIMIDE |
Labeler Name | Parke-Davis Div of Pfizer Inc |
Pharmaceutical Class | Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA010596 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00071-0525-24 (00071052524)
NDC Package Code | 0071-0525-24 |
---|---|
Billing NDC | 00071052524 |
Package | 100 CAPSULE in 1 BOTTLE (0071-0525-24) |
Marketing Start Date | 1957-02-08 |
NDC Exclude Flag | N |
Pricing Information | N/A |